Theratechnologies Inc., a commercial-stage biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has approved the company’s supplemental Biologics License Application (sBLA) for the F8 formulation of tesamorelin for injection.  The company will commercialize the new formulation under the tradename EGRIFTA WR, replacing EGRIFTA SV. EGRIFTA WR is a daily injectable but only needs weekly reconstitution. It requires less than half the administration vo...